Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by emmitfitzhumeon Jan 03, 2016 7:16pm
137 Views
Post# 24426418

RE:Best Guesses for 2016

RE:Best Guesses for 2016Share Price: 22.00 Deals: 3 Thanks KBC. Looking forward to a great 2016 with Bioasis, it seems this company is ready to turn the proverbial corner, finally. The science remains outstanding, the message from management seems quite confident as of late, the challenge of drug delivery across the BBB remains elusive at this point, and the markets which exist at this point untapped with current medicine and technology are potentially massive (chronic pain, oncology, cerebral vascular disease/stroke, Alzheimer's/dementia, infectious disease, enzyme replacement, etc). The potential market sizes of any single one of these areas are mind boggling, given the strategy and business model of this company, they have a very legitimate chance of being involved in most or all of these potential markets, with little to no competition in a market that is for the taking in its current state. Good luck to all, thanks to those of you who continue to contribute greatly to the board with you insights and opinions, ie JD, KBC...
Bullboard Posts